In order to explore the effects of iberdomide on the differentiation of B cells in SLE, we adapted a previously described method for differentiating B cells into plasma cells, which includes stimulation with IL2, IL10, IL15 and CD40L, substituting TLR7 agonist Resiquimod instead of TLR9 agonist CpG. The gene discussed is IL15; the disease is systemic lupus erythematosus.